Bristol Myers
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
There's a good reason why AstraZeneca tanked when merger rumors hit the Street.
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
AstraZeneca-Bristol Myers: The Floodgates for Biotech Mergers Are Open
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
AstraZeneca, Bristol Myers Squibb To Merge? Let's Consider The Pros And Cons
Rumors swirl of an AstraZenecaâBristol Myers Squibb mega-merger: patent cliffs, oncology synergies, and key risksâget the stock takeaways now.
Why Is Bristol-Myers Squibb Stock Surging Monday?
Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the world's 4th-largest drugmaker.
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb mega-merger. Read why he thinks BMY 'needs help'.
Wall Street Breakfast Podcast: Say Hello To Qwen3.8-Max
Alibaba launches Qwen3.8-Max to challenge global rivals. Google pulls a new Earth feature. AstraZeneca and Bristol Myers explore potential mega-merger.
AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger
AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks ongoing for months, antitrust scrutiny is expected.
Key People
No individuals linked to this entity yet.
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro